



---

## **2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Virtual Meeting: Eisai Inc. Sponsored Research**

Please see the listing of Eisai Inc. sponsored research presented at 2021 ASCO-GU Cancers Symposium Virtual Meeting below and refer to the Congress Links section available on our Medical Information website which may include additional information.

### **RENAL CELL CARCINOMA**

1. Bergerot C, Rha S, Pal S, et al. Health-related quality of life outcomes from a phase 2 open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment. Poster presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Virtual Meeting; February 11 – 13, 2021; Virtual.
2. Pal S, Puente J, Heng DYC, et al. Phase 2 trial over lenvatinib (LEN) at 2 starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). Poster presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Virtual Meeting; February 11 – 13, 2021; Virtual.
3. Motzer R, Liu Y, Perini R, et al. Phase 3 study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy. Poster presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Virtual Meeting; February 11 – 13, 2021; Virtual.
4. Motzer R, Porta C, Eto M, et al. Phase 3 trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (CLEAR study). Oral presentation at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Virtual Meeting; February 11 – 13, 2021; Virtual.

### **IMPORTANT INFORMATION - PLEASE READ:**

If you would like a full copy of the publication(s) listed above, please submit your request via [www.eisaimedicalinformation.com/oncology/medicalinquiry](http://www.eisaimedicalinformation.com/oncology/medicalinquiry) or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at [esi\\_oncmedinfo@eisai.com](mailto:esi_oncmedinfo@eisai.com) or call 1-888-274-2378.